NO20060392L - Kombinasjon av SRC kinase inhibitorer kemoterapeutiske midler for behandling av proliferative sykdommer - Google Patents

Kombinasjon av SRC kinase inhibitorer kemoterapeutiske midler for behandling av proliferative sykdommer

Info

Publication number
NO20060392L
NO20060392L NO20060392A NO20060392A NO20060392L NO 20060392 L NO20060392 L NO 20060392L NO 20060392 A NO20060392 A NO 20060392A NO 20060392 A NO20060392 A NO 20060392A NO 20060392 L NO20060392 L NO 20060392L
Authority
NO
Norway
Prior art keywords
treatment
combination
chemotherapeutic agents
kinase inhibitors
proliferative diseases
Prior art date
Application number
NO20060392A
Other languages
English (en)
Inventor
Francis Y F Lee
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of NO20060392L publication Critical patent/NO20060392L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Preparater og metoder er beskrevet som er anvendehge for behandling og forebygging av prohferative lidelser.
NO20060392A 2003-07-09 2006-01-24 Kombinasjon av SRC kinase inhibitorer kemoterapeutiske midler for behandling av proliferative sykdommer NO20060392L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48577903P 2003-07-09 2003-07-09
PCT/US2004/021890 WO2005013983A1 (en) 2003-07-09 2004-07-09 Combination of src kinase inhibitors and chemotherapeutic agents for the treatment of proliferative diseases

Publications (1)

Publication Number Publication Date
NO20060392L true NO20060392L (no) 2006-02-03

Family

ID=34135068

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20060392A NO20060392L (no) 2003-07-09 2006-01-24 Kombinasjon av SRC kinase inhibitorer kemoterapeutiske midler for behandling av proliferative sykdommer

Country Status (20)

Country Link
US (2) US20050009891A1 (no)
EP (1) EP1643996A4 (no)
JP (1) JP2007528849A (no)
KR (1) KR20060032627A (no)
CN (1) CN1849119A (no)
AU (1) AU2004263095B2 (no)
BR (1) BRPI0411864A (no)
CA (1) CA2531675A1 (no)
GE (1) GEP20094677B (no)
IL (1) IL173008A0 (no)
IS (1) IS8221A (no)
MX (1) MXPA06000191A (no)
NO (1) NO20060392L (no)
NZ (1) NZ544587A (no)
RS (1) RS20060011A (no)
RU (1) RU2006103858A (no)
TW (1) TW200505443A (no)
UA (1) UA83850C2 (no)
WO (1) WO2005013983A1 (no)
ZA (1) ZA200600176B (no)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3222619A1 (en) 1999-04-15 2017-09-27 Bristol-Myers Squibb Holdings Ireland Cyclic protein tyrosine kinase inhibitors
US7491725B2 (en) * 2004-02-06 2009-02-17 Bristol-Myers Squibb Company Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
BRPI0510095A (pt) * 2004-04-20 2007-10-16 Transtech Pharma Inc tiazol substituìdo e derivados de pirimidina como moduladores de receptores de melanocortina
TW200628156A (en) * 2004-11-04 2006-08-16 Bristol Myers Squibb Co Combination of a SRC kinase inhibitor and a BCR-ABL inhibitor for the treatment of proliferative diseases
PE20061394A1 (es) * 2005-03-15 2006-12-15 Bristol Myers Squibb Co Metabolitos de n-(2-cloro-6-metilfenil)-2-[[6-[4-(2-hidroxietil)-1-piperazinil]-2-metil-4-pirimidinil]amino]-5-tiazolcarboxamidas
US20060235006A1 (en) * 2005-04-13 2006-10-19 Lee Francis Y Combinations, methods and compositions for treating cancer
CA2610157A1 (en) * 2005-06-09 2006-12-21 Bristol-Myers Squibb Company Methods of identifying and treating individuals exhibiting mutant kit protein
EP1937270A1 (en) * 2005-09-21 2008-07-02 Brystol-Myers Squibb Company Oral administration of n-(2-chloro-6-methylphenyl)-2-[[6-4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-1,3-thiazole-5-carboxamide and salts thereof
US20070093499A1 (en) * 2005-10-20 2007-04-26 Bristol-Myers Squibb Company Use of dasatinib for the treatment of bone metastasis
WO2007059143A2 (en) * 2005-11-15 2007-05-24 Bristol-Myers Squibb Company Methods of identifying and treating individuals exhibiting mdr-1 overexpression with protein tyrosine kinase inhibitors and combinations thereof
US20090306094A1 (en) * 2006-03-17 2009-12-10 Bristol-Myers Squibb Company Methods Of Identifying And Treating Individuals Exhibiting Mutant Bcr/Abl Kinase Polypeptides
EP2425840B1 (en) * 2006-12-15 2015-04-08 Abraxis BioScience, Inc. Triazine derivatives and their therapeutical applications
GB0625691D0 (en) * 2006-12-22 2007-01-31 Astrazeneca Ab Combination product
CN101265275B (zh) * 2007-02-16 2012-09-05 中国医学科学院药物研究所 4-{6-[5-(2-氯-6-甲基苯胺甲酰基)-噻唑-2-氨基]-2-甲基嘧啶-4}-哌嗪-1-磷酸二乙酯
WO2011011027A1 (en) * 2009-07-20 2011-01-27 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
US8119129B2 (en) 2008-08-01 2012-02-21 Bristol-Myers Squibb Company Combination of anti-CTLA4 antibody with dasatinib for the treatment of proliferative diseases
WO2010025142A1 (en) * 2008-08-29 2010-03-04 Transtech Pharma, Inc. Substituted aminothiazole derivatives, pharmaceutical compositions, and methods of use
MX367055B (es) 2012-06-26 2019-08-02 Del Mar Pharmaceuticals El uso de una composición que comprende dianhidrogalactitol, diacetildianhidrogalactitol, y dibromodulcitol, y análogos o derivados de cada uno para el tratamiento de malignidades resistentes a inhibidores de tirosina cinasa.
JP7409696B2 (ja) 2018-06-15 2024-01-09 ハンダ ファーマシューティカルズ インコーポレイテッド キナーゼ阻害剤の塩およびその組成物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5051910A (en) * 1989-10-16 1991-09-24 Honeywell Inc. Wind forecast error compensation for 4-D guidance in a aircraft flight management system
US5121325A (en) * 1990-04-04 1992-06-09 Smiths Industries Aerospace & Defense Systems, Inc. Required time of arrival (RTA) control system
ZA200007412B (en) * 1998-05-15 2002-03-12 Imclone Systems Inc Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
EP3222619A1 (en) * 1999-04-15 2017-09-27 Bristol-Myers Squibb Holdings Ireland Cyclic protein tyrosine kinase inhibitors
US7125875B2 (en) 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
US6507782B1 (en) * 2001-05-14 2003-01-14 Honeywell International Inc. Aircraft control system for reaching a waypoint at a required time of arrival
CA2810339A1 (en) 2001-08-10 2003-02-20 Novartis Ag Use of c-src inhibitors alone or in combination with sti571 for the treatment of leukaemia
US20040209930A1 (en) * 2002-10-02 2004-10-21 Carboni Joan M. Synergistic methods and compositions for treating cancer
US20050215795A1 (en) * 2004-02-06 2005-09-29 Bang-Chi Chen Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
US7652146B2 (en) * 2004-02-06 2010-01-26 Bristol-Myers Squibb Company Process for preparing 2-aminothiazole-5-carboxamides useful as kinase inhibitors

Also Published As

Publication number Publication date
KR20060032627A (ko) 2006-04-17
EP1643996A4 (en) 2009-06-03
US20080153842A1 (en) 2008-06-26
CN1849119A (zh) 2006-10-18
UA83850C2 (ru) 2008-08-26
CA2531675A1 (en) 2005-02-17
NZ544587A (en) 2009-07-31
MXPA06000191A (es) 2006-04-11
GEP20094677B (en) 2009-05-10
AU2004263095B2 (en) 2009-10-29
BRPI0411864A (pt) 2006-08-08
AU2004263095A1 (en) 2005-02-17
RU2006103858A (ru) 2006-06-27
JP2007528849A (ja) 2007-10-18
IL173008A0 (en) 2006-06-11
WO2005013983A1 (en) 2005-02-17
ZA200600176B (en) 2010-06-30
TW200505443A (en) 2005-02-16
EP1643996A1 (en) 2006-04-12
RS20060011A (en) 2007-12-31
US7622472B2 (en) 2009-11-24
IS8221A (is) 2006-01-06
US20050009891A1 (en) 2005-01-13

Similar Documents

Publication Publication Date Title
NO20060392L (no) Kombinasjon av SRC kinase inhibitorer kemoterapeutiske midler for behandling av proliferative sykdommer
NO20034056L (no) Kombinasjoner av epotilonanaloger og kjemoterapeutiske midler for behandling av proliferative sykdommer
NO20082880L (no) Inhibitorer av C-MET samt anvendelse derav
TW200801008A (en) Protein kinase inhibitors
HK1092467A1 (en) N-alkyl-hydroxamic acid-isoindolyl compounds and their pharmaceutical uses n-
NO20055894L (no) Fremgangsmater og blandinger for behandling av amyloidrelatertere sykdommer
NO20085373L (no) P38 inhibitorer, deres fremstilling og anvendelse
EA200900802A1 (ru) Способы и композиции для лечения амилоидных заболеваний
NO20072567L (no) Triazoler nyttige som proteinkinase-inhibitorer
EA200700333A1 (ru) Терапевтические применения ингибиторов rtp801
NO20082026L (no) Deazapuriner som er nyttige som inhibitorer for Janus-kinaser
WO2007050793A3 (en) Methods and compositions for the treatment of marfan syndrome and associated disorders
NO20072179L (no) Kombinasjon av en SRC kinase inhibitor og en. BCR-ABL inhibitor for behandling av proleferative sykdommer
NO20052359D0 (no) Karbostyilderivater og serotonin reopptaks inhibitorer for behandling av humor forsyrrelser
WO2003065987A3 (en) Granzyme b inhibitors
WO2007016338A3 (en) Use of chk2 kinase inhibitors for cancer treatment
DK1641803T3 (da) Thienopyrimidinderivater som kaliumkanalinhibitorer
MX2021013602A (es) Inhibidores de jak.
NO20073725L (no) CCI-779-polymorf og dens anvendelse
WO2005007123A3 (en) Pin1-modulating compounds and methods of use thereof
TW200716561A (en) P38 inhibitors and methods of use thereof
DE60329326D1 (de) Tace inhibitoren
MX2022001702A (es) Inhibidores de jak.
UA92465C2 (ru) Терапевтические применения ингибиторов rtp801

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application